TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News

USA - NYSE:TAK - US8740602052 - ADR

14.29 USD

+0.05 (+0.35%)

Last: 11/14/2025, 8:04:00 PM

14.29 USD

0 (0%)

After Hours: 11/14/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TAK Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: NBIX

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

8 days ago - By: Zacks Investment Research - Mentions: BIIB ALKS DNLI

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

8 days ago - By: Takeda Pharmaceutical Company Limited

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

12 days ago - By: Takeda Pharmaceutical Company Limited

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

16 days ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

16 days ago - By: Takeda Pharmaceutical Company Limited

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

19 days ago - By: Takeda Pharmaceutical Company Limited

HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation

5 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

24 days ago - By: Innovent Biologics

News Image

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

24 days ago - By: Takeda Pharmaceutical Company Limited

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

2 months ago - By: Takeda Pharmaceutical Company Limited

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

2 months ago - By: The Motley Fool - Mentions: MO PFE XOM BTI

5 Best High-Yield Dividend Stocks to Buy Now

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

2 months ago - By: Takeda Pharmaceutical Company Limited

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

3 months ago - By: Yahoo Finance

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

4 months ago - By: Investor's Business Daily - Mentions: RY RY.CA ALKS CNTA ...

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

4 months ago - By: Yahoo Finance

Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

5 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

5 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces New Assignments of Directors

5 months ago - By: Takeda Pharmaceutical Company Limited

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

6 months ago - By: Takeda Pharmaceutical Company Limited - Mentions: PTGX

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

6 months ago - By: Takeda Pharmaceutical Company Limited

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

6 months ago - By: Yahoo Finance - Mentions: MSFT VRT NVDA META ...

Build 2025 Highlights Microsoft (MSFT)’s Push Toward a Collaborative AI Future